This SuperSeries is composed of the SubSeries listed below.
Overall design: Refer to individual Series
| Accession | PRJNA174125; GEO: GSE40476 |
| Type | Umbrella project |
| Submission | Registration date: 29-Aug-2012
Constellation Pharmaceuticals |
| Relevance | Superseries |
Project Data:
| Resource Name | Number
of Links |
|---|
| Sequence data |
| SRA Experiments | 24 |
| Other datasets |
| BioSample | 24 |
| GEO DataSets | 5 |
GEO Data Details| Parameter | Value |
|---|
| Data volume, Spots | 44022 |
| Data volume, Processed Mbytes | 1 |
| Data volume, Supplementary Mbytes | 13847 |
| Parameter | Value |
|---|
| Data volume, Gbases | 63 |
| Data volume, Mbytes | 43240 |
Selective lymphoma cell killing by a PRC2 small molecule inhibitor encompasses the following 4 sub-projects:
| Project Type | Number of Projects |
| Epigenomics | 2 |
BioProject
accession | Organism | Title |
|---|
| PRJNA174126 | Homo sapiens | Selective lymphoma cell killing by a PRC2 small molecule inhibitor (ChIP-Seq set 1) (Constellation Pharmaceuticals) | | PRJNA174127 | Homo sapiens | Selective lymphoma cell killing by a PRC2 small molecule inhibitor (ChIP-Seq set 2) (Constellation Pharmaceuticals) |
|
| Transcriptome or Gene expression | 2 |
BioProject
accession | Organism | Title |
|---|
| PRJNA174128 | Homo sapiens | Selective lymphoma cell killing by a PRC2 small molecule inhibitor (Exon array) (Constellation Pharmaceuticals) | | PRJNA174129 | Homo sapiens | Selective lymphoma cell killing by a PRC2 small molecule inhibitor (RNA-Seq) (Constellation Pharmaceuticals) |
|